Myrtelle
Myrtelle Inc.
Myrtelle Inc. is a clinical-stage gene therapy company carrying the mission of developing innovative treatments for neurodegenerative diseases that primarily affect myelin and white matter in the brain. With a particular focus on Canavan disease, the company addresses critical gaps in treatment options for rare genetic disorders of the central nervous system, aiming to improve patient outcomes significantly.
Products & Team
rAAV-Olig001-ASPA
rAAV-Olig001-ASPA is an investigational gene therapy specifically designed to treat Canavan disease, a severe childhood genetic disorder characterized by the degeneration of white matter in the brain.
This therapy addresses the urgent need for effective treatments for Canavan disease, moving beyond palliative care to potentially halt and reverse neurological decline.
Families face a dire lack of effective treatment options, with existing therapies mainly providing palliative care without addressing the underlying genetic cause.